The Efficacy of Rupatadine fumarate on Pain

Study of the Efficacy of Rupatadine fumarate for Postherpetic Neuralgia - SERPN trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs021190010

Enrollment

Registered

2019-10-18

Start date

2020-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster

Interventions

after diagnosis of herpes zoster, in addition to the conventional treatment, Rupatazine fumarate is given 10 mg / day per day for 13 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) age:20-years-old or older 2) patients with acute herpes zoster within 2 weeks

Exclusion criteria

Exclusion criteria: 1) patients with severe liver, kidney, heart disease, or diabetes 2) patients receiving medications that affect pain 3) patients with hypersensitivity to rupatazine fumarate 4) pregnant and nursing patients

Design outcomes

Primary

Measure	Time frame
Improvement rate of the visual analogue scale (VAS)	—

Secondary

Measure	Time frame
Improvement rate of The Dermatology Life Quality Index (DLQI)	—

Contacts

Public Contactmichihiro kono

Akita University Hospital

miro@med.akita-u.ac.jp+81-18-884-6153

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026